The 2011 Drug Patent ‘Cliff’ And The Evolution Of IP Valuation 11/01/2011 by Liza Porteus Viana, Intellectual Property Watch 1 Comment In today’s global economy, there is an increasing convergence of intellectual property and finance. Wall Street is grappling with how to recognise the true value of a firm’s intellectual property. Companies are realising that simply accumulating patents does not necessarily increase their firms’ value, but it is how those patents are used that can attract capital. And drug companies facing massive numbers of upcoming patent expiries, a deflated economy and other market pressures, are looking to diversify their portfolios to stay in the black.
The Top Legal IP Issues In The United States In 2011 07/01/2011 by Steven Seidenberg for Intellectual Property Watch Leave a Comment The year 2010 was a turbulent year for intellectual property law in the United States, and 2011 promises more of the same. The following are some of the top US IP developments to watch in the coming year.
Special Report: Music Industry’s Lavish Lobby Campaign For Digital Rights 06/01/2011 by Bruce Gain for Intellectual Property Watch 13 Comments The music industry has spent tens of millions of dollars to lobby government officials worldwide during the past decade, but whether or not the initiative has helped to shape a viable legal and commercial framework is a subject of debate.
Patent On AIDS Medicine Denied In India; Seen Unlocking Market 04/01/2011 by Catherine Saez, Intellectual Property Watch 2 Comments A decision by the Indian Patent Office to reject a patent on an AIDS drug last week has drawn acclaim from civil society and Indian generic pharmaceutical industries. The decision was not based on a controversial article of Indian law aimed at preventing patent extensions but rather on the grounds of non-inventiveness. Abbott Laboratories, meanwhile, presented Intellectual Property Watch with justification for its Indian patent request.
Top IP-Watch Stories Of 2010: Copyright Fights, ACTA, Medicines Access 30/12/2010 by William New and Catherine Saez, Intellectual Property Watch Leave a Comment At Intellectual Property Watch, a list of the top 25 posts of 2010 reveals your – our readers’ – top interests and tells the tale of the past year. It also is a reminder that quality reporting needs support. Please subscribe to IP-Watch via our website, or contact the director at wnew@ip-watch.ch.
US Industrial Policies, R&D, And The WTO’s Definition Of Non-Actionable Subsidies 23/12/2010 by Intellectual Property Watch 3 Comments The US organizes a sophisticated industrial policy regime by exploiting an exception in the World Trade Organization agreement that allows governments to subsidize research and development carried out by private firms, writes Professor Fred Block.
Both Sides Of US Copyright Wars Reloading For 2011 20/12/2010 by William New, Intellectual Property Watch Leave a Comment Two sides of the ongoing struggle to balance stronger copyright protection and access to knowledge in the United States are re-arming themselves for battle in 2011. By the looks of it, it could be a litigious New Year.
US Ambassador: Over-Focus On Development “Will Kill” WIPO 17/12/2010 by William New, Intellectual Property Watch 5 Comments The World Intellectual Property Organization is headed in a controversial direction, and a focus on development at the expense of protection of intellectual property rights will mean the end of the agency, the United States Ambassador Betty King said yesterday.
US Ambassador In Geneva Defends Secrecy In UN Pandemics Negotiations 17/12/2010 by William New, Intellectual Property Watch 1 Comment The United States Ambassador to the United Nations in Geneva this week offered a frank assessment of the UN system of dealing with pandemic diseases, and defended the need for governments to negotiate in secret to work out remaining differences.
Efforts To Limit Effects Of TRIPS In India Might Not Be Working, Study Says 17/12/2010 by Catherine Saez, Intellectual Property Watch Leave a Comment Strategies may be failing to ensure developing countries’ implementation of global trade rules for intellectual property protection does not squelch access to affordable medicines worldwide, according to a study presented this week.